UPDATE 1-GSK seeks EU marketing approval for lupus drug

* Says to seek U.S. FDA approval by end June

* Submission includes results from 2 late-stage trials

June 7 (BestGrowthStock) – GlaxoSmithKline Plc (GSK.L: ) has sought
European regulators’ marketing approval for its experimental
lupus drug Benlysta, being developed along with Human Genome
Sciences Inc (HGSI.O: ), the companies said.

The submission to the European Medicines Agency (EMA)
includes results from two late-stage trials, Human Genome said.

If approved, the drug will be the first treatment for lupus
— a complex disease that causes the immune system to attack
the body’s own tissue and organs — in 50 years.

GSK said it plans to submit a Biologics License Application
for the drug to the U.S. Food and Drug Administration later
this month.

Benlysta is being developed by GSK and Human Genome under a
co-development and marketing agreement signed in 2006.

Stock Market Trading

(Reporting by Shailesh Kuber in Bangalore; Editing by
Gopakumar Warrier)

UPDATE 1-GSK seeks EU marketing approval for lupus drug